IL6 and cardiovascular disorder: The ZEUS study is now underway to evaluate the effect of IL-6 inhibition with ziltivekimab in patients with cardiovascular disease, chronic kidney disease and inflammation (ClinicalTrials.gov Identifier: NCT05021835).